Table 4 Characteristics of CAR-T cell patients according to the outcome at 1 year
From: The use of ICU resources in CAR-T cell recipients: a hospital-wide study
N (%) or Median (IQR] | 1-year survivors (n = 45) | 1-year decedents (n = 26) | p |
|---|---|---|---|
Demographics | |||
Age | 60 [32–68] | 58 [41–65] | 0∙84 |
Male gender | 24 (53%) | 18 (69%) | 0∙29 |
Comorbidities | |||
Hypertension | 4 (9%) | 6 (23%) | 0.19 |
Diabetes | 3 (7%) | 1 (4%) | 1 |
Chronic kidney disease | 2 (4.5%) | 0 | 0.73 |
Body mass index (kg/m2) | 24.5 [22–27] | 23.5 [22–25.5] | 0.40 |
Performance status | 1 [1–2] | 2 [1–2] | 0.023 |
Hematological malignancy | 0.73 | ||
Diffuse large B cell lymphoma | 33 (73%) | 20 (77%) | |
Lymphoblastic leukemia | 11 (24.5%) | 6 (23%) | |
Multiple myeloma | 1 (2%) | 0 | |
Median number of previous treatment lines | 3 [2–4] | 4 [3–5] | 0.12 |
Time between CAR-T cell infusion and ICU admission (days) | 6 [4–8] | 5 [3–7] | 0.21 |
Reason for ICU admission | 0.04 | ||
CRS | 22 (49%) | 11 (42%) | |
CRS or sepsis | 10 (22%) | 3 (11.5%) | |
Sepsis | 13 (29%) | 8 (31%) | |
Disease progression | 0 | 4 (15.5%) | |
Clinical and biological features at ICU admission | |||
Mean arterial blood pressure (mmHg) | 66 [60–78] | 70 [63–82] | 0.24 |
Temperature ( °C) | 39.9 [38.9–40.3] | 38.9 [38–39.7] | 0.003 |
Neutropenia | 25 (55.5%) | 22 (85%) | 0.02 |
SOFA score | 4 [2–6] | 5 [2–7] | 0.21 |
Non-specific treatments in the ICU at day 1 | |||
Fluid resuscitation at day 1 (mL) | 1000 [0–2000] | 500 [0–1500] | 0.23 |
Vasopressors | 10 (22%) | 8 (31%) | 0.61 |
Mechanical ventilation | 2 (4.5%) | 0 | 0.73 |
Renal replacement therapy | 0 | 1 (4%) | 0.78 |